U.S. markets open in 2 hours 42 minutes
  • S&P Futures

    3,911.00
    -11.50 (-0.29%)
     
  • Dow Futures

    31,927.00
    +11.00 (+0.03%)
     
  • Nasdaq Futures

    13,173.75
    -128.25 (-0.96%)
     
  • Russell 2000 Futures

    2,291.50
    +6.40 (+0.28%)
     
  • Crude Oil

    63.22
    0.00 (0.00%)
     
  • Gold

    1,785.70
    -12.20 (-0.68%)
     
  • Silver

    28.06
    +0.13 (+0.45%)
     
  • EUR/USD

    1.2228
    +0.0060 (+0.49%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    22.66
    -0.45 (-1.95%)
     
  • GBP/USD

    1.4129
    -0.0013 (-0.09%)
     
  • USD/JPY

    106.1570
    +0.2750 (+0.26%)
     
  • BTC-USD

    49,883.11
    -683.97 (-1.35%)
     
  • CMC Crypto 200

    998.43
    +3.77 (+0.38%)
     
  • FTSE 100

    6,681.81
    +22.84 (+0.34%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
  • Oops!
    Something went wrong.
    Please try again later.

In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $165.99, marking a -1.96% move from the previous day. This change lagged the S&P 500's daily loss of 0.75%. At the same time, the Dow lost 0.61%, and the tech-heavy Nasdaq lost 0.57%.

Coming into today, shares of the company had gained 2.21% in the past month. In that same time, the Medical sector lost 4.67%, while the S&P 500 gained 4%.

Wall Street will be looking for positivity from GWPH as it approaches its next earnings report date. This is expected to be May 6, 2019. In that report, analysts expect GWPH to post earnings of -$2.48 per share. This would mark year-over-year growth of 20.51%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.27 million, up 534.96% from the year-ago period.

Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 7.06% higher. GWPH currently has a Zacks Rank of #2 (Buy).

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 180, putting it in the bottom 30% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.